Human cellular models for the investigation of lung inflammation and mucus production in cystic fibrosis

Analytical Cellular Pathology

Volumn 2018, Issue , 2018, Pages

  Castellani, Stefano ^a   Di Gioia, Sante ^a   di Toma, Lorena ^a   Conese, Massimo ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LEAD;

AIRWAY EPITHELIUM CELL; AIRWAY REMODELING; COCULTURE; CYSTIC FIBROSIS; DENDRITIC CELL; EPITHELIUM CELL; FIBROBLAST; HUMAN; HUMAN CELL CULTURE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INFLAMMATION; MACROPHAGE; MESENCHYME CELL; MICROFLUIDICS; MUCUS SECRETION; PNEUMONIA; RESPIRATORY EPITHELIUM; REVIEW; TISSUE ENGINEERING; BIOLOGICAL MODEL; METABOLISM; MUCUS; PATHOLOGY; PATHOPHYSIOLOGY;

AIRWAY REMODELING; CYSTIC FIBROSIS; HUMANS; MODELS, BIOLOGICAL; MUCUS; PNEUMONIA; TISSUE ENGINEERING;

EID: 85058922236     PISSN: 22107177     EISSN: 22107185     Source Type: Journal    
DOI: 10.1155/2018/3839803     Document Type: Review

References (159)

1. R. C. Boucher, “Cystic fibrosis: a disease of vulnerability to airway surface dehydration,” Trends in Molecular Medicine, vol. 13, no. 6, pp. 231–240, 2007.
2. V. L. Campodonico, M. Gadjeva, C. Paradis-Bleau, A. Uluer, and G. B. Pier, “Airway epithelial control of Pseudomonas aeruginosa infection in cystic fibrosis,” Trends in Molecular Medicine, vol. 14, no. 3, pp. 120–133, 2008.
3. P. S. Salva, N. A. Doyle, L. Graham, H. Eigen, and C. M. Doerschuk, “TNF-alpha, IL-8, soluble ICAM-1, and neutrophils in sputum of cystic fibrosis patients,” Pediatric Pulmonology, vol. 21, no. 1, pp. 11–19, 1996.
4. T. L. Bonfield, M. W. Konstan, and M. Berger, “Altered respiratory epithelial cell cytokine production in cystic fibrosis,” The Journal of Allergy and Clinical Immunology, vol. 104, no. 1, pp. 72–78, 1999.
5. D. G. Downey, S. C. Bell, and J. S. Elborn, “Neutrophils in cystic fibrosis,” Thorax, vol. 64, no. 1, pp. 81–88, 2009.
6. A. C. Tang, S. E. Turvey, M. P. Alves, N. Regamey, B. Tummler, and D. Hartl, “Current concepts: host-pathogen interactions in cystic fibrosis airways disease,” European Respiratory Review, vol. 23, no. 133, pp. 320–332, 2014.
7. C. A. Hobbs, C. Da Tan, and R. Tarran, “Does epithelial sodium channel hyperactivity contribute to cystic fibrosis lung disease?,” The Journal of Physiology, vol. 591, no. 18, pp. 4377–4387, 2013.
8. R. C. Boucher, “Evidence for airway surface dehydration as the initiating event in CF airway disease,” Journal of Internal Medicine, vol. 261, no. 1, pp. 5–16, 2007.
9. D. F. Rogers, “Mucoactive agents for airway mucus hypersecretory diseases,” Respiratory Care, vol. 52, pp. 1176–1197, 2007.
10. A. Munder and B. Tümmler, “Origins of cystic fibrosis lung disease,” The New England Journal of Medicine, vol. 372, no. 16, pp. 1574-1575, 2015.
11. L. W. Velsor, A. van Heeckeren, and B. J. Day, “Antioxidant imbalance in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 281, no. 1, pp. L31–L38, 2001.
12. B. J. Day, A. M. van Heeckeren, E. Min, and L. W. Velsor, “Role for cystic fibrosis transmembrane conductance regulator protein in a glutathione response to bronchopulmonary pseudomonas infection,” Infection and Immunity, vol. 72, no. 4, pp. 2045–2051, 2004.
13. N. S. Gould, E. Min, R. J. Martin, and B. J. Day, “CFTR is the primary known apical glutathione transporter involved in cigarette smoke-induced adaptive responses in the lung,” Free Radical Biology & Medicine, vol. 52, no. 7, pp. 1201–1206, 2012.
14. A. G. Ziady and J. Hansen, “Redox balance in cystic fibrosis,” The International Journal of Biochemistry & Cell Biology, vol. 52, pp. 113–123, 2014.
15. A. McCarron, M. Donnelley, and D. Parsons, “Airway disease phenotypes in animal models of cystic fibrosis,” Respiratory Research, vol. 19, no. 1, p. 54, 2018.
16. G. M. Lavelle, M. M. White, N. Browne, N. G. McElvaney, and E. P. Reeves, “Animal models of cystic fibrosis pathology: phenotypic parallels and divergences,” BioMed Research International, vol. 2016, Article ID 5258727, 14 pages, 2016.
17. B. H. Rosen, M. Chanson, L. R. Gawenis et al., “Animal and model systems for studying cystic fibrosis,” Journal of Cystic Fibrosis, vol. 17, no. 2, pp. S28–S34, 2018.
18. M. E. Egan, “How useful are cystic fibrosis mouse models?,” Drug Discovery Today: Disease Models, vol. 6, no. 2, pp. 35–41, 2009.
19. R. J. Pack, L. H. Al-Ugaily, and G. Morris, “The cells of the tracheobronchial epithelium of the mouse: a quantitative light and electron microscope study,” Journal of Anatomy, vol. 132, Part 1, pp. 71–84, 1981.
20. K. L. Tuggle, S. E. Birket, X. Cui et al., “Characterization of defects in ion transport and tissue development in cystic fibrosis transmembrane conductance regulator (CFTR)knockout rats,” PLoS One, vol. 9, no. 3, article e91253, 2014.
21. X. Sun, H. Sui, J. T. Fisher et al., “Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis,” The Journal of Clinical Investigation, vol. 120, no. 9, pp. 3149–3160, 2010.
22. C. S. Rogers, Y. Hao, T. Rokhlina et al., “Production of CFTR-null and CFTR-DeltaF508 heterozygous pigs by adeno-associated virus-mediated gene targeting and somatic cell nuclear transfer,” The Journal of Clinical Investigation, vol. 118, no. 4, pp. 1571–1577, 2008.
23. N. Klymiuk, L. Mundhenk, K. Kraehe et al., “Sequential targeting of CFTR by BAC vectors generates a novel pig model of cystic fibrosis,” Journal of Molecular Medicine, vol. 90, no. 5, pp. 597–608, 2012.
24. A. Ralhan, J. Laval, F. Lelis et al., “Current concepts and controversies in innate immunity of cystic fibrosis lung disease,” Journal of Innate Immunity, vol. 8, no. 6, pp. 531–540, 2016.
25. D. P. Nichols, M. W. Konstan, and J. F. Chmiel, “Anti-inflammatory therapies for cystic fibrosis-related lung disease,” Clinical Reviews in Allergy and Immunology, vol. 35, no. 3, pp. 135–153, 2008.
26. S. D. Sagel, B. D. Wagner, M. M. Anthony, P. Emmett, and E. T. Zemanick, “Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 186, no. 9, pp. 857–865, 2012.
27. M. Conese, S. A. Tirelli, G. Alicandro et al., “Biomarkers of inflammation and remodelling in cystic fibrosis,” Clinical Immunology, Endocrine & Metabolic Drugs, vol. 3, no. 2, pp. 92–108, 2017.
28. N. Sanders, C. Rudolph, K. Braeckmans, S. C. De Smedt, and J. Demeester, “Extracellular barriers in respiratory gene therapy,” Advanced Drug Delivery Reviews, vol. 61, no. 2, pp. 115–127, 2009.
29. G. A. Duncan, J. Jung, J. Hanes, and J. S. Suk, “The mucus barrier to inhaled gene therapy,” Molecular Therapy, vol. 24, no. 12, pp. 2043–2053, 2016.
30. M. Conese, S. Castellani, S. D'Oria, and P. Montemurro, “Role of neutrophils in cystic fibrosis lung disease,” in Role of Neutrophils in Disease Pathogenesis, M. Khajah, Ed., pp. 119–141, IntechOpen Limited, London, England, 2017.
31. P. S. Hiemstra, P. B. McCray Jr, and R. Bals, “The innate immune function of airway epithelial cells in inflammatory lung disease,” The European Respiratory Journal, vol. 45, no. 4, pp. 1150–1162, 2015.
32. P. G. Holt, M. A. Schon-Hegrad, and P. G. McMenamin, “Dendritic cells in the respiratory tract,” International Reviews of Immunology, vol. 6, no. 2-3, pp. 139–149, 1990.
33. B. E. Lehnert, “Pulmonary and thoracic macrophage subpop-ulations and clearance of particles from the lung,” Environmental Health Perspectives, vol. 97, pp. 17–46, 1992.
34. E. M. Bruscia and T. L. Bonfield, “Cystic fibrosis lung immunity: the role of the macrophage,” Journal of Innate Immunity, vol. 8, no. 6, pp. 550–563, 2016.
35. E. M. Bruscia and T. L. Bonfield, “Innate and adaptive immunity in cystic fibrosis,” Clinics in Chest Medicine, vol. 37, no. 1, pp. 17–29, 2016.
36. L. S. Ostedgaard, T. O. Moninger, J. D. McMenimen et al., “Gel-forming mucins form distinct morphologic structures in airways,” Proceedings of the National Academy of Sciences of the United States of America, vol. 114, pp. 6842–6847, 2017.
37. P. M. Quinton, “Birth of mucus,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 298, no. 1, pp. L13–L14, 2010.
38. E. Y. T. Chen, N. Yang, P. M. Quinton, and W.-C. Chin, “A new role for bicarbonate in mucus formation,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 299, no. 4, pp. L542–L549, 2010.
39. S. M. Kreda, C. W. Davis, and M. C. Rose, “CFTR, mucins, and mucus obstruction in cystic fibrosis,” Cold Spring Harbor Perspectives in Medicine, vol. 2, no. 9, 2012.
40. + absorption produces cystic fibrosis-like lung disease in mice,” Nature Medicine, vol. 10, no. 5, pp. 487–493, 2004.
41. M. A. Mall, J. R. Harkema, J. B. Trojanek et al., “Development of chronic bronchitis and emphysema in beta-epithelial Na+ channel-overexpressing mice,” American Journal of Respiratory and Critical Care Medicine, vol. 177, no. 7, pp. 730–742, 2008.
42. Z. Zhou, J. Duerr, B. Johannesson et al., “The ENaC-overexpressing mouse as a model of cystic fibrosis lung disease,” Journal of Cystic Fibrosis, vol. 10, Supplement 2, pp. S172–S182, 2011.
43. X. Sun, A. K. Olivier, B. Liang et al., “Lung phenotype of juvenile and adult cystic fibrosis transmembrane conductance regulator-knockout ferrets,” American Journal of Respiratory Cell and Molecular Biology, vol. 50, no. 3, pp. 502–512, 2014.
44. D. A. Stoltz, D. K. Meyerholz, A. A. Pezzulo et al., “Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth,” Science Translational Medicine, vol. 2, no. 29, article 29ra31, 2010.
45. L. S. Ostedgaard, D. K. Meyerholz, J. H. Chen et al., “The ΔF508 mutation causes CFTR misprocessing and cystic fibrosis–like disease in pigs,” Science Translational Medicine, vol. 3, no. 74, article 74ra24, 2011.
46. R. J. Adam, A. S. Michalski, C. Bauer et al., “Air trapping and airflow obstruction in newborn cystic fibrosis piglets,” American Journal of Respiratory and Critical Care Medicine, vol. 188, no. 12, pp. 1434–1441, 2013.
47. P. R. Burgel and J. A. Nadel, “Roles of epidermal growth factor receptor activation in epithelial cell repair and mucin production in airway epithelium,” Thorax, vol. 59, no. 11, pp. 992–996, 2004.
48. J. A. Voynow, L. R. Young, Y. Wang, T. Horger, M. C. Rose, and B. M. Fischer, “Neutrophil elastase increases MUC5AC mRNA and protein expression in respiratory epithelial cells,” The American Journal of Physiology, vol. 276, 5 Part 1, pp. L835–L843, 1999.
49. K. Kohri, I. F. Ueki, and J. A. Nadel, “Neutrophil elastase induces mucin production by ligand-dependent epidermal growth factor receptor activation,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 283, no. 3, pp. L531–L540, 2002.
50. H. Ishimoto, H. Mukae, N. Sakamoto et al., “Different effects of telithromycin on MUC5AC production induced by human neutrophil peptide-1 or lipopolysaccharide in NCI-H292 cells compared with azithromycin and clarithromycin,” The Journal of Antimicrobial Chemotherapy, vol. 63, no. 1, pp. 109–114, 2009.
51. S. Rajan, G. Cacalano, R. Bryan et al., “Pseudomonas aeruginosa induction of apoptosis in respiratory epithelial cells. Analysis of the effects of cystic fibrosis transmembrane conductance regulator dysfunction and bacterial virulence factors,” American Journal of Respiratory Cell and Molecular Biology, vol. 23, no. 3, pp. 304–312, 2000.
52. S. Halldorsson, T. Gudjonsson, M. Gottfredsson, P. K. Singh, G. H. Gudmundsson, and O. Baldursson, “Azithromycin maintains airway epithelial integrity during Pseudomonas aeruginosa infection,” American Journal of Respiratory Cell and Molecular Biology, vol. 42, no. 1, pp. 62–68, 2010.
53. M. W. Leigh, J. E. Kylander, J. R. Yankaskas, and R. C. Boucher, “Cell proliferation in bronchial epithelium and submucosal glands of cystic fibrosis patients,” American Journal of Respiratory Cell and Molecular Biology, vol. 12, no. 6, pp. 605–612, 1995.
54. H. A. W. M. Tiddens, L. P. Koopman, R. K. Lambert et al., “Cartilaginous airway wall dimensions and airway resistance in cystic fibrosis lungs,” The European Respiratory Journal, vol. 15, no. 4, pp. 735–742, 2000.
55. C. Hubeau, M. Lorenzato, J. P. Couetil et al., “Quantitative analysis of inflammatory cells infiltrating the cystic fibrosis airway mucosa,” Clinical and Experimental Immunology, vol. 124, no. 1, pp. 69–76, 2001.
56. J. A. Voynow, B. M. Fischer, B. C. Roberts, and A. D. Proia, “Basal-like cells constitute the proliferating cell population in cystic fibrosis airways,” American Journal of Respiratory and Critical Care Medicine, vol. 172, no. 8, pp. 1013–1018, 2005.
57. T. Piorunek, A. Marszalek, W. Biczysko, J. Gozdzik, S. Cofta, and M. Seget, “Correlation between the stage of cystic fibrosis and the level of morphological changes in adult patients,” Journal of Physiology and Pharmacology, vol. 59, Supplement 6, pp. 565–572, 2008.
58. N. T. N. Trinh, O. Bardou, A. Privé et al., “Improvement of defective cystic fibrosis airway epithelial wound repair after CFTR rescue,” The European Respiratory Journal, vol. 40, no. 6, pp. 1390–1400, 2012.
59. N. Regamey, P. K. Jeffery, E. W. F. W. Alton, A. Bush, and J. C. Davies, “Airway remodelling and its relationship to inflammation in cystic fibrosis,” Thorax, vol. 66, no. 7, pp. 624–629, 2011.
60. T. N. Hilliard, N. Regamey, J. K. Shute et al., “Airway remodelling in children with cystic fibrosis,” Thorax, vol. 62, no. 12, pp. 1074–1080, 2007.
61. R. Hajj, P. Lesimple, B. Nawrocki-Raby, P. Birembaut, E. Puchelle, and C. Coraux, “Human airway surface epithelial regeneration is delayed and abnormal in cystic fibrosis,” The Journal of Pathology, vol. 211, no. 3, pp. 340–350, 2007.
62. J. Bérubé, L. Roussel, L. Nattagh, and S. Rousseau, “Loss of cystic fibrosis transmembrane conductance regulator function enhances activation of p38 and ERK MAPKs, increasing interleukin-6 synthesis in airway epithelial cells exposed to Pseudomonas aeruginosa,” The Journal of Biological Chemistry, vol. 285, no. 29, pp. 22299–22307, 2010.
63. S. Kim, B. A. Beyer, C. Lewis, and J. A. Nadel, “Normal CFTR inhibits epidermal growth factor receptor-dependent pro-inflammatory chemokine production in human airway epithelial cells,” PLoS One, vol. 8, no. 8, article e72981, 2013.
64. C. Martin, N. Coolen, Y. Wu et al., “CFTR dysfunction induces vascular endothelial growth factor synthesis in airway epithelium,” The European Respiratory Journal, vol. 42, no. 6, pp. 1553–1562, 2013.
65. C. Berasain and M. A. Avila, “Amphiregulin,” Seminars in Cell & Developmental Biology, vol. 28, pp. 31–41, 2014.
66. J. Jacquot, O. Tabary, P. le Rouzic, and A. Clement, “Airway epithelial cell inflammatory signalling in cystic fibrosis,” The International Journal of Biochemistry & Cell Biology, vol. 40, no. 9, pp. 1703–1715, 2008.
67. C. M. Greene, T. P. Carroll, S. G. J. Smith et al., “TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells,” Journal of Immunology, vol. 174, no. 3, pp. 1638–1646, 2005.
68. L. Guillot, S. Medjane, K. le-Barillec et al., “Response of human pulmonary epithelial cells to lipopolysaccharide involves toll-like receptor 4 (TLR4)-dependent signaling pathways: evidence for an intracellular compartmentalization of TLR4,” The Journal of Biological Chemistry, vol. 279, no. 4, pp. 2712–2718, 2004.
69. A. Crabbe, M. A. Ledesma, and C. A. Nickerson, “Mimicking the host and its microenvironment in vitro for studying mucosal infections by Pseudomonas aeruginosa,” Pathogens and Disease, vol. 71, no. 1, pp. 1–19, 2014.
70. M. Kelly, S. Trudel, F. Brouillard et al., “Cystic fibrosis transmembrane regulator inhibitors CFTR(inh)-172 and GlyH-101 target mitochondrial functions, independently of chloride channel inhibition,” The Journal of Pharmacology and Experimental Therapeutics, vol. 333, no. 1, pp. 60–69, 2010.
71. G. Veit, F. Bossard, J. Goepp et al., “Proinflammatory cytokine secretion is suppressed by TMEM16A or CFTR channel activity in human cystic fibrosis bronchial epithelia,” Molecular Biology of the Cell, vol. 23, no. 21, pp. 4188–4202, 2012.
72. I. Virella-Lowell, J. D. Herlihy, B. Liu et al., “Effects of CFTR, interleukin-10, and Pseudomonas aeruginosa on gene expression profiles in a CF bronchial epithelial cell line,” Molecular Therapy, vol. 10, no. 3, pp. 562–573, 2004.
73. V. Balloy, H. Varet, M. A. Dillies et al., “Normal and cystic fibrosis human bronchial epithelial cells infected with Pseudomonas aeruginosa exhibit distinct gene activation patterns,” PLoS One, vol. 10, no. 10, article e0140979, 2015.
74. N. Reiniger, J. K. Ichikawa, and G. B. Pier, “Influence of cystic fibrosis transmembrane conductance regulator on gene expression in response to Pseudomonas aeruginosa infection of human bronchial epithelial cells,” Infection and Immunity, vol. 73, no. 10, pp. 6822–6830, 2005.
75. M. C. Dechecchi, E. Nicolis, V. Bezzerri et al., “MPB-07 reduces the inflammatory response to Pseudomonas aeruginosa in cystic fibrosis bronchial cells,” American Journal of Respiratory Cell and Molecular Biology, vol. 36, no. 5, pp. 615–624, 2007.
76. M. Brodlie, M. C. McKean, G. E. Johnson et al., “Primary bronchial epithelial cell culture from explanted cystic fibrosis lungs,” Experimental Lung Research, vol. 36, no. 2, pp. 101–110, 2010.
77. S. A. Molina, B. Stauffer, H. K. Moriarty, A. H. Kim, N. A. McCarty, and M. Koval, “Junctional abnormalities in human airway epithelial cells expressing F508del CFTR,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 309, no. 5, pp. L475–L487, 2015.
78. B. Q. Shen, W. E. Finkbeiner, J. J. Wine, R. J. Mrsny, and J. H. Widdicombe, “Calu-3: a human airway epithelial cell line that shows cAMP-dependent Cl- secretion,” The American Journal of Physiology, vol. 266, 5 Part 1, pp. L493–L501, 1994.
79. J. Huang, D. Kim, J. Shan, A. Abu-Arish, Y. Luo, and J. W. Hanrahan, “Most bicarbonate secretion by Calu-3 cells is mediated by CFTR and independent of pendrin,” Physiological Reports, vol. 6, no. 5, article e13641, 2018.
80. P. LeSimple, J. Liao, R. Robert, D. C. Gruenert, and J. W. Hanrahan, “Cystic fibrosis transmembrane conductance regulator trafficking modulates the barrier function of airway epithelial cell monolayers,” The Journal of Physiology, vol. 588, no. 8, pp. 1195–1209, 2010.
81. S. H. Randell, M. L. Fulcher, W. O’Neal, and J. C. Olsen, “Primary epithelial cell models for cystic fibrosis research,” Methods in Molecular Biology, vol. 742, pp. 285–310, 2011.
82. M. L. Fulcher, S. Gabriel, K. A. Burns, J. R. Yankaskas, and S. H. Randell, “Well-differentiated human airway epithelial cell cultures,” Methods in Molecular Medicine, vol. 107, pp. 183–206, 2005.
83. R. Villenave, M. D. Shields, and U. F. Power, “Respiratory syncytial virus interaction with human airway epithelium,” Trends in Microbiology, vol. 21, no. 5, pp. 238–244, 2013.
84. A. A. Pezzulo, T. D. Starner, T. E. Scheetz et al., “The air-liquid interface and use of primary cell cultures are important to recapitulate the transcriptional profile of in vivo airway epithelia,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 300, no. 1, pp. L25–L31, 2011.
85. A. Dvorak, A. E. Tilley, R. Shaykhiev, R. Wang, and R. G. Crystal, “Do airway epithelium air-liquid cultures represent the in vivo airway epithelium transcriptome?,” American Journal of Respiratory Cell and Molecular Biology, vol. 44, no. 4, pp. 465–473, 2011.
86. A. Muir, G. Soong, S. Sokol et al., “Toll-like receptors in normal and cystic fibrosis airway epithelial cells,” American Journal of Respiratory Cell and Molecular Biology, vol. 30, no. 6, pp. 777–783, 2004.
87. S. F. Vencken and C. M. Greene, “Toll-like receptors in cystic fibrosis: impact of dysfunctional microRNA on innate immune responses in the cystic fibrosis lung,” Journal of Innate Immunity, vol. 8, no. 6, pp. 541–549, 2016.
88. G. Voisin, G. F. Bouvet, P. Legendre, A. Dagenais, C. Massé, and Y. Berthiaume, “Oxidative stress modulates the expression of genes involved in cell survival in ΔF508 cystic fibrosis airway epithelial cells,” Physiological Genomics, vol. 46, no. 17, pp. 634–646, 2014.
89. A. Schögler, F. Blank, M. Brügger et al., “Characterization of pediatric cystic fibrosis airway epithelial cell cultures at the air-liquid interface obtained by non-invasive nasal cytology brush sampling,” Respiratory Research, vol. 18, no. 1, p. 215, 2017.
90. M. N. Becker, M. S. Sauer, M. S. Muhlebach et al., “Cytokine secretion by cystic fibrosis airway epithelial cells,” American Journal of Respiratory and Critical Care Medicine, vol. 169, no. 5, pp. 645–653, 2004.
91. K. Mosler, C. Coraux, K. Fragaki et al., “Feasibility of nasal epithelial brushing for the study of airway epithelial functions in CF infants,” Journal of Cystic Fibrosis, vol. 7, no. 1, pp. 44–53, 2008.
92. D. M. Comer, J. S. Elborn, and M. Ennis, “Comparison of nasal and bronchial epithelial cells obtained from patients with COPD,” PLoS One, vol. 7, no. 3, article e32924, 2012.
93. M. P. Alves, A. Schögler, S. Ebener et al., “Comparison of innate immune responses towards rhinovirus infection of primary nasal and bronchial epithelial cells,” Respirology, vol. 21, no. 2, pp. 304–312, 2016.
94. L. M. Yonker, H. Mou, K. K. Chu et al., “Development of a primary human co-culture model of inflamed airway mucosa,” Scientific Reports, vol. 7, no. 1, p. 8182, 2017.
95. S. Castellani, L. Guerra, M. Favia, S. di Gioia, V. Casavola, and M. Conese, “NHERF1 and CFTR restore tight junction orga-nisation and function in cystic fibrosis airway epithelial cells: role of ezrin and the RhoA/ROCK pathway,” Laboratory Investigation, vol. 92, no. 11, pp. 1527–1540, 2012.
96. O. A. Forrest, S. A. Ingersoll, M. K. Preininger et al., “Front-line science: pathological conditioning of human neutrophils recruited to the airway milieu in cystic fibrosis,” Journal of Leukocyte Biology, vol. 104, no. 4, pp. 665–675, 2018.
97. H. Grassmé, B. Henry, R. Ziobro et al., “β1-Integrin accumulates in cystic fibrosis luminal airway epithelial membranes and decreases sphingosine, promoting bacterial infections,” Cell Host & Microbe, vol. 21, no. 6, pp. 707–718.e8, 2017.
98. V. Teichgräber, M. Ulrich, N. Endlich et al., “Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis,” Nature Medicine, vol. 14, no. 4, pp. 382–391, 2008.
99. K. A. Becker, B. Henry, R. Ziobro, B. Tümmler, E. Gulbins, and H. Grassmé, “Role of CD95 in pulmonary inflammation and infection in cystic fibrosis,” Journal of Molecular Medicine, vol. 90, no. 9, pp. 1011–1023, 2012.
100. D. Adam, J. Roux-Delrieu, E. Luczka et al., “Cystic fibrosis airway epithelium remodelling: involvement of inflammation,” The Journal of Pathology, vol. 235, no. 3, pp. 408–419, 2015.
101. L. J. Galietta, C. Folli, E. Caci et al., “Effect of inflammatory stimuli on airway ion transport,” Proceedings of the American Thoracic Society, vol. 1, no. 1, pp. 62–65, 2004.
102. L. J. V. Galietta, C. Folli, C. Marchetti et al., “Modification of transepithelial ion transport in human cultured bronchial epithelial cells by interferon-γ,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 278, no. 6, pp. L1186–L1194, 2000.
103. H. Danahay, H. Atherton, G. Jones, R. J. Bridges, and C. T. Poll, “Interleukin-13 induces a hypersecretory ion transport phenotype in human bronchial epithelial cells,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 282, no. 2, pp. L226–L236, 2002.
104. L. J. V. Galietta, P. Pagesy, C. Folli et al., “IL-4 is a potent modulator of ion transport in the human bronchial epithelium in vitro,” Journal of Immunology, vol. 168, no. 2, pp. 839–845, 2002.
105. P. Scudieri, E. Caci, S. Bruno et al., “Association of TMEM16A chloride channel overexpression with airway goblet cell metaplasia,” The Journal of Physiology, vol. 590, no. 23, pp. 6141–6155, 2012.
106. K. Tiringer, A. Treis, P. Fucik et al., “A Th17- and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection,” American Journal of Respiratory and Critical Care Medicine, vol. 187, no. 6, pp. 621–629, 2013.
107. S. Nyabam, Z. Wang, T. Thibault et al., “A novel regulatory role for tissue transglutaminase in epithelial-mesenchymal transition in cystic fibrosis,” Biochimica et Biophysica Acta, vol. 1863, no. 9, pp. 2234–2244, 2016.
108. M. Stolarczyk, G. Veit, A. Schnúr, M. Veltman, G. L. Lukacs, and B. J. Scholte, “Extracellular oxidation in cystic fibrosis airway epithelium causes enhanced EGFR/ADAM17 activity,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 314, no. 4, pp. L555–L568, 2018.
109. M. Stolarczyk and B. J. Scholte, “The EGFR-ADAM17 axis in chronic obstructive pulmonary disease and cystic fibrosis lung pathology,” Mediators of Inflammation, vol. 2018, Article ID 1067134, 22 pages, 2018.
110. N. W. Keiser, S. E. Birket, I. A. Evans et al., “Defective innate immunity and hyperinflammation in newborn cystic fibrosis transmembrane conductance regulator-knockout ferret lungs,” American Journal of Respiratory Cell and Molecular Biology, vol. 52, no. 6, pp. 683–694, 2015.
111. D. Parker and A. Prince, “Innate immunity in the respiratory epithelium,” American Journal of Respiratory Cell and Molecular Biology, vol. 45, no. 2, pp. 189–201, 2011.
112. E. G. Lavoie, T. Wangdi, and B. I. Kazmierczak, “Innate immune responses to Pseudomonas aeruginosa infection,” Microbes and Infection, vol. 13, no. 14-15, pp. 1133–1145, 2011.
113. T. S. Cohen and A. Prince, “Cystic fibrosis: a mucosal immunodeficiency syndrome,” Nature Medicine, vol. 18, no. 4, pp. 509–519, 2012.
114. S. L. Peterson-Carmichael, W. T. Harris, R. Goel et al., “Association of lower airway inflammation with physiologic findings in young children with cystic fibrosis,” Pediatric Pulmonology, vol. 44, no. 5, pp. 503–511, 2009.
115. S. C. Ranganathan, F. Parsons, C. Gangell et al., “Evolution of pulmonary inflammation and nutritional status in infants and young children with cystic fibrosis,” Thorax, vol. 66, no. 5, pp. 408–413, 2011.
116. H. Grasemann and F. Ratjen, “Cystic fibrosis lung disease: the role of nitric oxide,” Pediatric Pulmonology, vol. 28, no. 6, pp. 442–448, 1999.
117. J. A. Bartlett, S. Ramachandran, C. L. Wohlford-Lenane et al., “Newborn cystic fibrosis pigs have a blunted early response to an inflammatory stimulus,” American Journal of Respiratory and Critical Care Medicine, vol. 194, no. 7, pp. 845–854, 2016.
118. L. Paemka, B. N. McCullagh, M. H. Abou Alaiwa et al., “Monocyte derived macrophages from CF pigs exhibit increased inflammatory responses at birth,” Journal of Cystic Fibrosis, vol. 16, no. 4, pp. 471–474, 2017.
119. E. M. Bruscia, P. X. Zhang, A. Satoh et al., “Abnormal trafficking and degradation of TLR4 underlie the elevated inflammatory response in cystic fibrosis,” Journal of Immunology, vol. 186, no. 12, pp. 6990–6998, 2011.
120. E. M. Bruscia, P. X. Zhang, E. Ferreira et al., “Macrophages directly contribute to the exaggerated inflammatory response in cystic fibrosis transmembrane conductance regulator−/− mice,” American Journal of Respiratory Cell and Molecular Biology, vol. 40, no. 3, pp. 295–304, 2009.
121. D. Papazian, P. A. Würtzen, and S. W. K. Hansen, “Polarized airway epithelial models for immunological co-culture studies,” International Archives of Allergy and Immunology, vol. 170, no. 1, pp. 1–21, 2016.
122. A. Kato and R. P. Schleimer, “Beyond inflammation: airway epithelial cells are at the interface of innate and adaptive immunity,” Current Opinion in Immunology, vol. 19, no. 6, pp. 711–720, 2007.
123. R. P. Schleimer, A. P. Lane, and J. Kim, “Innate and acquired immunity and epithelial cell function in chronic rhinosinusi-tis,” Clinical Allergy and Immunology, vol. 20, pp. 51–78, 2007.
124. S. A. Saenz, B. C. Taylor, and D. Artis, “Welcome to the neighborhood: epithelial cell-derived cytokines license innate and adaptive immune responses at mucosal sites,” Immunological Reviews, vol. 226, no. 1, pp. 172–190, 2008.
125. M. J. Holtzman, D. E. Byers, J. Alexander-Brett, and X. Wang, “The role of airway epithelial cells and innate immune cells in chronic respiratory disease,” Nature Reviews Immunology, vol. 14, no. 10, pp. 686–698, 2014.
126. D. Papazian, S. Hansen, and P. A. Würtzen, “Airway responses towards allergens - from the airway epithelium to T cells,” Clinical and Experimental Allergy, vol. 45, no. 8, pp. 1268–1287, 2015.
127. B. Bleck, D. B. Tse, M. A. Curotto de Lafaille, F. Zhang, and J. Reibman, “Diesel exhaust particle-exposed human bronchial epithelial cells induce dendritic cell maturation and polarization via thymic stromal lymphopoietin,” Journal of Clinical Immunology, vol. 28, no. 2, pp. 147–156, 2008.
128. A. Rate, J. W. Upham, A. Bosco, K. L. McKenna, and P. G. Holt, “Airway epithelial cells regulate the functional phenotype of locally differentiating dendritic cells: implications for the pathogenesis of infectious and allergic airway disease,” Journal of Immunology, vol. 182, no. 1, pp. 72–83, 2008.
129. B. Bleck, D. B. Tse, T. Gordon, M. R. Ahsan, and J. Reibman, “Diesel exhaust particle-treated human bronchial epithelial cells upregulate Jagged-1 and OX40 ligand in myeloid dendritic cells via thymic stromal lymphopoietin,” Journal of Immunology, vol. 185, no. 11, pp. 6636–6645, 2010.
130. D. Papazian, V. R. Wagtmann, S. Hansen, and P. A. Würtzen, “Direct contact between dendritic cells and bronchial epithelial cells inhibits T cell recall responses towards mite and pollen allergen extracts in vitro,” Clinical and Experimental Immunology, vol. 181, no. 2, pp. 207–218, 2015.
131. F. Blank, B. Rothen-Rutishauser, and P. Gehr, “Dendritic cells and macrophages form a transepithelial network against foreign particulate antigens,” American Journal of Respiratory Cell and Molecular Biology, vol. 36, no. 6, pp. 669–677, 2007.
132. A. D. Lehmann, N. Daum, M. Bur, C. M. Lehr, P. Gehr, and B. M. Rothen-Rutishauser, “An in vitro triple cell co-culture model with primary cells mimicking the human alveolar epithelial barrier,” European Journal of Pharmaceutics and Bio-pharmaceutics, vol. 77, no. 3, pp. 398–406, 2011.
133. A. K. Mayer, H. Bartz, F. Fey, L. M. Schmidt, and A. H. Dalpke, “Airway epithelial cells modify immune responses by inducing an anti-inflammatory microenvironment,” European Journal of Immunology, vol. 38, no. 6, pp. 1689–1699, 2008.
134. H. Kumon, K. Sasaki, Y. Ariyoshi et al., “Feasibility of neoad-juvant ad-REIC gene therapy in patients with high-risk localized prostate cancer undergoing radical prostatectomy,” Clinical and Translational Science, vol. 8, no. 6, pp. 837–840, 2015.
135. F. Demayo, P. Minoo, C. G. Plopper, L. Schuger, J. Shannon, and J. S. Torday, “Mesenchymal-epithelial interactions in lung development and repair: are modeling and remodeling the same process?,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 283, no. 3, pp. L510–L517, 2002.
136. A. B. Thompson, R. A. Robbins, D. J. Romberger et al., “Immunological functions of the pulmonary epithelium,” The European Respiratory Journal, vol. 8, no. 1, pp. 127–149, 1995.
137. M. M. Myerburg, J. D. Latoche, E. E. McKenna et al., “Hepa-tocyte growth factor and other fibroblast secretions modulate the phenotype of human bronchial epithelial cells,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 292, no. 6, pp. L1352–L1360, 2007.
138. F. Huaux, S. Noel, B. Dhooghe et al., “Dysregulated proin-flammatory and fibrogenic phenotype of fibroblasts in cystic fibrosis,” PLoS One, vol. 8, no. 5, article e64341, 2013.
139. L. Wiszniewski, L. Jornot, T. Dudez et al., “Long-term cultures of polarized airway epithelial cells from patients with cystic fibrosis,” American Journal of Respiratory Cell and Molecular Biology, vol. 34, no. 1, pp. 39–48, 2006.
140. S. F. Chou, S. W. Chang, and J. L. Chuang, “Mitomycin C upregulates IL-8 and MCP-1 chemokine expression via mitogen-activated protein kinases in corneal fibroblasts,” Investigative Ophthalmology & Visual Science, vol. 48, no. 5, pp. 2009–2016, 2007.
141. A. Bielemeier, Development of a Multicellular Co-Culture Model of Normal and Cystic Fibrosis Human Airways In Vitro, Aston University, Birmimgham, Enland, 2011.
142. A. Carbone, S. Castellani, M. Favia et al., “Correction of defective CFTR/ENaC function and tightness of cystic fibrosis airway epithelium by amniotic mesenchymal stromal (stem) cells,” Journal of Cellular and Molecular Medicine, vol. 18, no. 8, pp. 1631–1643, 2014.
143. A. Carbone, R. Zefferino, E. Beccia et al., “Gap junctions are involved in the rescue of CFTR-dependent chloride efflux by amniotic mesenchymal stem cells in coculture with cystic fibrosis CFBE41o- cells,” Stem Cells International, vol. 2018, Article ID 1203717, 14 pages, 2018.
144. A. J. Carterson, K. Honer zu Bentrup, C. M. Ott et al., “A549 lung epithelial cells grown as three-dimensional aggregates: alternative tissue culture model for Pseudomonas aeruginosa pathogenesis,” Infection and Immunity, vol. 73, no. 2, pp. 1129–1140, 2005.
145. S. Ravindran, Y. Song, and A. George, “Development of three-dimensional biomimetic scaffold to study epithelial-mesenchymal interactions,” Tissue Engineering. Part A, vol. 16, no. 1, pp. 327–342, 2010.
146. S. Ishikawa, K. Ishimori, and S. Ito, “A 3D epithelial-mesenchymal co-culture model of human bronchial tissue recapitulates multiple features of airway tissue remodeling by TGF-β1 treatment,” Respiratory Research, vol. 18, no. 1, p. 195, 2017.
147. A. T. N. Hoang, P. Chen, J. Juarez et al., “Dendritic cell functional properties in a three-dimensional tissue model of human lung mucosa,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 302, no. 2, pp. L226–L237, 2012.
148. H. Harrington, P. Cato, F. Salazar et al., “Immunocompetent 3D model of human upper airway for disease modeling and in vitro drug evaluation,” Molecular Pharmaceutics, vol. 11, no. 7, pp. 2082–2091, 2014.
149. M. Ulrich and G. Doring, “Three-dimensional human airway epithelial cell cultures,” Journal of Cystic Fibrosis, vol. 3, Supplement 2, pp. 55–57, 2004.
150. M. Ulrich, J. Berger, J. G. Möller, and G. Döring, “Moxiflox-acin and ciprofloxacin protect human respiratory epithelial cells against Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, and Haemophilus influenzae in vitro,” Infection, vol. 33, no. S2, Supplement 2, pp. 50–54, 2005.
151. Q. Tan, K. M. Choi, D. Sicard, and D. J. Tschumperlin, “Human airway organoid engineering as a step toward lung regeneration and disease modeling,” Biomaterials, vol. 113, pp. 118–132, 2017.
152. A. Crabbé, S. F. Sarker, R. van Houdt et al., “Alveolar epithelium protects macrophages from quorum sensing-induced cytotoxicity in a three-dimensional co-culture model,” Cellular Microbiology, vol. 13, no. 3, pp. 469–481, 2011.
153. D. C. Wilkinson, J. A. Alva-Ornelas, J. M. S. Sucre et al., “Development of a three-dimensional bioengineering technology to generate lung tissue for personalized disease modeling,” Stem Cells Translational Medicine, vol. 6, no. 2, pp. 622–633, 2017.
154. D. E. Wagner, R. W. Bonvillain, T. Jensen et al., “Can stem cells be used to generate new lungs? Ex vivo lung bioengineering with decellularized whole lung scaffolds,” Respirology, vol. 18, no. 6, pp. 895–911, 2013.
155. E. A. Calle, M. Ghaedi, S. Sundaram, A. Sivarapatna, M. K. Tseng, and L. E. Niklason, “Strategies for whole lung tissue engineering,” IEEE Transactions on Biomedical Engineering, vol. 61, no. 5, pp. 1482–1496, 2014.
156. M. E. Scarrit, N. C. Pashos, and B. A. Bunnell, “A review of cellularization strategies for tissue engineering of whole organs,” Frontiers in Bioengineering and Biotechnology, vol. 3, 2015.
157. R. LaRanger, J. R. Peters-Hall, M. Coquelin et al., “Reconstituting mouse lungs with conditionally reprogrammed human bronchial epithelial cells,” Tissue Engineering Part A, vol. 24, no. 7-8, pp. 559–568, 2018.
158. P. Kumar, N. E. Vrana, and A. M. Ghaemmaghami, “Prospects and challenges in engineering functional respiratory epithelium for in vitro and in vivo applications,” Microphy-siological Systems, vol. 1, 2017.
159. C. Blume, R. Reale, M. Held et al., “Temporal monitoring of differentiated human airway epithelial cells using microflui-dics,” PLoS One, vol. 10, no. 10, article e0139872, 2015.